ScripsAmerica Launches RapiMed To Beat Tylenol Meltaways

ScripsAmerica Inc.’s new RapiMed line of orally dissolving pediatric painkillers seeks to beat McNeil Consumer Healthcare’s Tylenol Meltaways’ return to the market and steal share from private label by promising to melt faster, taste better and cost less. The products also address FDA dosing concerns and target Hispanic shoppers.

More from Marketing & Advertising

More from Compliance